(Press-News.org) German researchers have identified an unexpected molecular marker that predicts how sensitive hard-to-treat triple-negative breast cancers are to chemotherapy.
Triple-negative breast cancers --which do not express the genes for estrogen receptor, or progesterone receptor and do not have Her2/neu overexpression or amplification-- are more aggressive than other forms of the disease and cannot be treated with endocrine or Her2 targeted therapies.
At the IMPAKT Breast Cancer Conference in Brussels, PhD student Carolin Huelsewig and Dr Cornelia Liedtke from Uniklinikum Muenster report that the molecule sFRP1 is much more highly expressed in these cancers, and that levels of the molecule in an individual tumor correlate with its sensitivity to chemotherapy.
The researchers undertook their study in three steps. First they conducted a gene expression analysis in breast cancer tissue samples, looking specifically for genes whose expression level differed between triple-negative cancers and non-triple negative cancers.
That analysis revealed that sFRP1 was the most highly overexpressed gene in triple-negative cancers relative to others. "The degree of difference was up to 4.7-fold in triple-negative vs. non-triple negative cancers," Ms Huelsewig said.
The results were a surprise, as sFRP1 is known to inhibit a signaling pathway within cells that is associated with the development of cancers. "The results of the differential gene expression analysis were initially astounding as sFRP1 has so far been understood as an antagonist within the wnt signaling cascade."
The researchers then tested genes for an association with relapse-free survival and response to neoadjuvant chemotherapy, finding that while sFRP1 expression was not associated with recurrence-free survival, it was significantly correlated with an increased sensitivity to chemotherapy.
Finally, the researchers conducted 'knockdown' experiments in cell culture, using the triple-negative breast cancer cell line MDA-MB 468. These experiments involved using short segments of RNA, known as siRNA, designed to block the expression of sFRP1. In breast cancer cells where sFRP1 expression was knocked down, there was significantly decreased sensitivity to paclitaxel, doxorubicin and cisplatinum, they found.
"It is increasingly recognized that molecular subtypes of breast cancer may be examined and characterized individually --including the revealing of a potentially very distinct set of biomarkers and therapeutic tools. Our results suggest sFRP1 signaling as a biomarker tailored to the triple-negative breast cancer subtype," Ms Huelsewig said.
"It is important to recognize that our results are not ready to be transferred into the clinic just yet," she said. "However, our approach provides proof-of-principle that identification, validation and functional analysis of biomarkers for specific disease subtypes is feasible through translational research incorporating both in-silico analyses such as gene expression profiling and basic science including functional analyses."
Commenting on the study, which he was not involved in, Dr Stephen Johnston, from Royal Marsden NHS Foundation Trust & Institute of Cancer Research, highlighted that Triple Negative Breast Cancer (TNBC) is a sub-type that despite its response to chemotherapy, carries a bad prognosis.
"Understanding the molecular profile which drives this disease is crucial to allow us to use existing drugs better, as well as find more effective treatments. In both clinical and laboratory experiments these researchers have identified a gene called sFRP1 involved in the wnt signalling cascade that is frequently over-expressed in TNBC, and may predict who responds best to chemotherapy – this could help select patients for treatment in the future."
INFORMATION: END
Two multi-gene tests designed to predict the risk of disease progression and response to chemotherapy in breast cancer produce broadly similar results for high- and low-risk patients, but do not always agree in their predictions for those at intermediate risk, a new analysis shows.
In recent years, several genomic tests have been developed to provide prognostic information for breast cancer. Dr Catherine Kelly from Mater Misericordiae University Hospital, Dublin, Ireland, and colleagues in the USA examined the agreement in prediction results between two multi-gene assays ...
Measuring the transfer of tiny amounts of energy from one protein to another on breast cancer cells has given scientists a detailed view of molecular interactions that could help predict how breast cancer patients will respond to particular therapies.
At the IMPAKT Breast Cancer Conference in Brussels, Dr Gargi Patel from the Richard Dimbleby Department, King's College London, described cutting-edge research in which she and colleagues captured detailed information about protein interactions on cancer cells, and correlated that with established genetic markers for cancer ...
The anti-inflammatory drug celecoxib may be a useful additional treatment for people with breast cancer, Dutch researchers report at the IMPAKT Breast Cancer Conference in Brussels.
The results of a randomized trial in 45 patients with primary invasive breast cancer showed that the drug --which is currently used to treat arthritis and other painful conditions-- clearly induced an anti-tumor response at the molecular level.
"This is exciting because it means that a medication already used to treat other diseases may be efficient in the adjuvant treatment of breast cancer ...
Domenico Di Ceglie, Director of Training and Research at the Gender Identity Development Service at the Tavistock and Portman NHS Foundation Trust in London, commented: "These are important findings in the field of gender incongruence, which need to be replicated. The awareness of the presence of autistic features may help these young people to explore the reasons behind their perceptions, and help them make more informed decisions about treatment."
Emma Martin, who runs a Gender Identity Support and research group in Little Downham, UK, welcomed the new findings, and ...
A new biosensor which uses antibody-based technology has been shown to detect marine pollutants such as oil cheaper and faster than current technology. Tests of the new biosensor, published in Environmental Toxicology and Chemistry, reveal how it could be used for the early detection and tracking of oil spills.
The biosensor has been developed by researchers at the Virginia Institute of Marine Science (VIMS) and was tested in the Elizabeth River and Yorktown Creek which both drain into Virginia's Chesapeake Bay.
"Our biosensor combines the power of the immune system ...
Spine Surgeon LA, the leading spine surgery specialists in the state of California has recently launched their website at the URL www.spinesurgeonla.com
Spine Surgeon LA is a medical hub wherein they treat and address several different types of spine problems. These spine problems include: Bulging Disc, Herniated Disc, Spine Scoliosis, Pinched Nerve, Spine Stenosis, Bone Spurs, and Spine Tumors among others. In their new website, spinesurgeonla.com, you may click on these common spine problems and then get a chance to read some information about them so that you may ...
Deadly human fungal infections caused by certain strains of Aspergillus fungi appear to be developing resistance to current drug treatments at an alarming rate, say scientists.
University of Manchester researchers, working with colleagues in Newark, USA, have developed a new test that can not only better diagnose Aspergillus infection, but can also spot signs of antifungal resistance to azoles – the class of drugs used to treat patients with aspergillosis.
Using the new test, which uses direct molecular detection rather than culturing the fungus in a Petri dish, the ...
The recent nuclear accident in Fukushima Daiichi in Japan has brought the nuclear debate to the forefront of controversy. While Japan is trying to avert further disaster, many nations are reconsidering the future of nuclear power in their regions. A study by Behnam Taebi from the Delft University of Technology, published online in the Springer journal Philosophy & Technology, reflects on the various possible nuclear power production methods from an ethical perspective: If we intend to continue with nuclear power production, which technology is most morally desirable?
On ...
(WASHINGTON) -- Researchers in the Materials Science and Technology division of the Naval Research Laboratory have recently demonstrated electrical injection, detection and precession of spin accumulation in silicon, the cornerstone material of modern device technology, at temperatures up to 225 degrees Celsius. These results provide the first demonstration that spin accumulation in Si is viable as a basis for practical devices which meet the operating temperatures specified for commercial (85˚C), industrial (100˚C) and military (125˚C) applications. This ...
Pan American Metals of Miami (PAMOM), continues to provide opportunities for investment in the bullion markets. "Precious metals are tried and tested and provide investors with a safe alternative to low interest rates and decreasing currency values," says Bill Hionas, CEO of PAMOM.
PAMOM deals in four precious metals; silver, gold, platinum and palladium. The current market is showing dips in all precious metal prices, providing savvy investors with a perfect opportunity to buy.
"Long-term predictions remain optimistic for the precious metals market, ...
